Sorrento Therapeutics Concludes Enrollment In Abivertinib Mid-Stage COVID-19 Trials In US, Brazil

by Vandana Singh, Benzinga Editor

June 22, 2021 11:01 AM | 24 seconds read |

Sorrento Therapeutics Inc SRNE has completed enrollment for its Phase 2 trial of Abivertinib in hospitalized COVID-19 patients in Brazil.
This study completion follows the recently completed enrollment of the U.S. Phase 2 clinical trial.
In two to three months, the company expects to be able to disclose top-line data.
Price Action: SRNE shares are down 1.73% at $8.54 during the market trading session on the last check Tuesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.